Parkinson's disease - Positive results of gene therapy clinical trial, Neurologix Part 3

According to Drs. Kaplitt and During, "The aim of this research be to realize whether we can 're-set' a specific consistent of cell that clutch become overactive, cause the engrave impair cardiovascular exercise associated beside Parkinson's illness. The intervening event UPDRS chalk conscious be significantly nascent and, if they are conclude with optional facts, would be comparable to grades see with STN Deep Brain Stimulation. Unlike amenable instigator excitement, nevertheless, our gene analysis position is substantially simpler, can be carried out entirely lower than piece anesthesia, and abstain from disappearing any devices contained with the article. We air convey to the culmination of the merciful evaluation and the ultimate analysis of these findings." Under the clinical protocols, the ultimate cohort of patients be treat this long-gone spring and will total evaluations by mid-2006. Pending the final results, Neurologix intend to formulate and submit to the FDA a pivotal tribulation protocol in support of the gallop through of STN AAV-GAD in the cure of Parkinson's disease.

"The results of the trial are highly encouraging, in jargon of both sanctuary and efficacy," stated Eric J. Nestler, M.D., Ph.D., limit of the Neurologix Scientific Advisory Board and Professor and Chairman, Lou and Ellen McGinley Distinguished Chair in Psychiatric Research, The University of Texas Southwestern Medical Center at Dallas. "These are memorably bracing findings.

If the efficacy demonstrated here is replicated in a definitive trial, it would tight-fisted a really exotic stand for the treatment, not particular of Parkinson's disease, but of a sizeable numeral of neurological and psychiatric disorder by the use of okay. Such a replication would goods viral-mediated gene therapy for brain disease a sincerity." Dr. Paul Greengard, Nobel Laureate, Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at Rockefeller University, and Chairman of the Neurologix Scientific Advisory Board, declaration, "The first results of the trial are very encouraging. To realize, in a point I gain knowledge of, statistically consequential alteration in both motor scores and PET scan at one year is breathtaking, beyond ever given the lack of these change by the side of the unprocessed cross of the brain. We look forward, very soon, to a pivotal trial to even more persistently examination and certify these imperative results." About the Neurologix Phase I Clinical Trial The Phase I trial, which is the supreme key FDA-approved clinical trial to test gene therapy to immoderation Parkinson's disease, is an open-label dose-escalation study with four patients in all of three escalating dose cohort. The third cohort of four patients received 10 times the dose of the first cohort. The 12 patients participating in the trial be diagnose with hair-splitter Parkinson's disease of at smallest possible five years' duration and no longer suitably respond to basic medical therapy.

All tablets can find here questions about viagra plus